BRPI0709157A8 - derivados de buprenorfina e usos dos mesmos - Google Patents

derivados de buprenorfina e usos dos mesmos

Info

Publication number
BRPI0709157A8
BRPI0709157A8 BRPI0709157A BRPI0709157A BRPI0709157A8 BR PI0709157 A8 BRPI0709157 A8 BR PI0709157A8 BR PI0709157 A BRPI0709157 A BR PI0709157A BR PI0709157 A BRPI0709157 A BR PI0709157A BR PI0709157 A8 BRPI0709157 A8 BR PI0709157A8
Authority
BR
Brazil
Prior art keywords
buprenorphine
derivatives
buprenorphine derivatives
enhanced
ester
Prior art date
Application number
BRPI0709157A
Other languages
English (en)
Portuguese (pt)
Inventor
Bourne Chapleo Christopher
William Lewis John
Original Assignee
Indivior Uk Ltd
Rb Pharmaceuticals Ltd
Reckitt Benkiser Healthcare Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indivior Uk Ltd, Rb Pharmaceuticals Ltd, Reckitt Benkiser Healthcare Uk Ltd filed Critical Indivior Uk Ltd
Publication of BRPI0709157A2 publication Critical patent/BRPI0709157A2/pt
Publication of BRPI0709157A8 publication Critical patent/BRPI0709157A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0709157A 2006-03-28 2007-03-27 derivados de buprenorfina e usos dos mesmos BRPI0709157A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0606124.6 2006-03-28
GBGB0606124.6A GB0606124D0 (en) 2006-03-28 2006-03-28 Buprenorphine derivatives and uses thereof
PCT/GB2007/001120 WO2007110636A1 (en) 2006-03-28 2007-03-27 Buprenorphine derivatives and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0709157A2 BRPI0709157A2 (pt) 2011-06-28
BRPI0709157A8 true BRPI0709157A8 (pt) 2018-04-24

Family

ID=36384277

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0709157A BRPI0709157A8 (pt) 2006-03-28 2007-03-27 derivados de buprenorfina e usos dos mesmos

Country Status (21)

Country Link
US (1) US7964610B2 (enExample)
EP (1) EP2001891B1 (enExample)
JP (1) JP5167446B2 (enExample)
KR (1) KR101430626B1 (enExample)
CN (2) CN104151320A (enExample)
AU (1) AU2007231133B2 (enExample)
BR (1) BRPI0709157A8 (enExample)
CA (1) CA2647417C (enExample)
DK (1) DK2001891T3 (enExample)
ES (1) ES2432169T3 (enExample)
GB (1) GB0606124D0 (enExample)
IL (1) IL193917A (enExample)
MX (1) MX2008011984A (enExample)
MY (1) MY151025A (enExample)
NZ (1) NZ570997A (enExample)
PL (1) PL2001891T3 (enExample)
PT (1) PT2001891E (enExample)
RU (1) RU2435773C2 (enExample)
TW (1) TWI501969B (enExample)
WO (1) WO2007110636A1 (enExample)
ZA (1) ZA200807614B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7511054B2 (en) 2006-09-22 2009-03-31 Alltranz Inc. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
PT2307420E (pt) * 2008-04-24 2012-02-14 Janssen Pharmaceutica Nv Pró-fármacos de di-éster de nalmefeno
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
MX2018004835A (es) * 2015-10-26 2018-08-01 Orphomed Inc Etilenglicol eter de buprenorfina.
CA3016510A1 (en) 2016-03-09 2017-09-14 Indivior Uk Limited Abuse-resistant pharmaceutical formulations
CN109789137B (zh) 2016-09-13 2023-01-13 昱展新药生技股份有限公司 丁丙诺啡缓释制剂
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
KR102839314B1 (ko) * 2018-05-11 2025-07-29 에일러 파마슈티컬스 아이엔씨. 오래 지속되는 주사용 제제와 부프레노핀 유도체
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2023102489A1 (en) * 2021-12-03 2023-06-08 Board Of Regents Of The University Of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction
CN116283893B (zh) * 2023-03-22 2024-04-26 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5750534A (en) 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
KR100204659B1 (ko) 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
US6225321B1 (en) 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
ES2298323T3 (es) 1998-11-13 2008-05-16 Jagotec Ag Inhalador de polvo seco multidosis con reserva de polvo.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
EP2517710B1 (en) 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
JP2005523876A (ja) 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー 乱用の可能性が低減したオピオイド製剤
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
AU2003285934A1 (en) * 2002-10-25 2004-05-25 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20050186139A1 (en) 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
RU2215741C1 (ru) * 2002-11-05 2003-11-10 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" Сложные эфиры n-замещенных 14-гидроксиморфинанов и способ их получения
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
ATE382050T1 (de) * 2002-11-25 2008-01-15 Chi Mei Foundation Medical Ct Buprenorphinesterderivate, verfahren zu ihrer herstellung, und langwirksame analgetische arzneimittel
JP2004175706A (ja) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
US7501113B2 (en) 2003-02-04 2009-03-10 Philip Morris Usa Inc. Aerosol formulations and aerosol delivery of buprenorphine
US7195882B2 (en) 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine

Also Published As

Publication number Publication date
JP5167446B2 (ja) 2013-03-21
RU2435773C2 (ru) 2011-12-10
CA2647417C (en) 2014-09-23
RU2008142527A (ru) 2010-05-10
MX2008011984A (es) 2008-10-03
EP2001891A1 (en) 2008-12-17
NZ570997A (en) 2011-08-26
TWI501969B (zh) 2015-10-01
CA2647417A1 (en) 2007-10-04
US20100234412A1 (en) 2010-09-16
PT2001891E (pt) 2013-10-30
WO2007110636A1 (en) 2007-10-04
BRPI0709157A2 (pt) 2011-06-28
EP2001891B1 (en) 2013-07-24
AU2007231133A8 (en) 2011-08-25
AU2007231133A1 (en) 2007-10-04
CN104151320A (zh) 2014-11-19
AU2007231133B2 (en) 2011-09-01
JP2009531406A (ja) 2009-09-03
AU2007231133A2 (en) 2008-10-16
PL2001891T3 (pl) 2014-03-31
GB0606124D0 (en) 2006-05-03
KR101430626B1 (ko) 2014-08-18
IL193917A (en) 2014-12-31
DK2001891T3 (da) 2013-11-04
CN101410402A (zh) 2009-04-15
ES2432169T3 (es) 2013-12-02
TW200806672A (en) 2008-02-01
KR20080105124A (ko) 2008-12-03
US7964610B2 (en) 2011-06-21
MY151025A (en) 2014-03-31
ZA200807614B (en) 2009-10-28

Similar Documents

Publication Publication Date Title
BRPI0709157A8 (pt) derivados de buprenorfina e usos dos mesmos
WO2010074588A3 (en) Pharmaceutical compounds
MX2020008890A (es) Metodos para reducir riesgo de evento cardiovascular en sujeto con terapia con estatina.
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
WO2006040688A3 (en) Inhibitors of acetylcholinesterase for treating skin diseases
ATE517611T1 (de) Darreichungsform enthaltend oxycodon und naloxon
BRPI0915300B8 (pt) compostos de éster boronato e composições farmacêuticas dos mesmos
EA200900741A1 (ru) Способы лечения гиперхолестеринемии
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
WO2011035335A3 (en) Stabilized liquid and lyophilized adamts13 formulations
WO2011026125A3 (en) Gastric retentive pharmaceutical compositions for immediate and extended release of acetaminophen
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
PT1998730T (pt) Novo sistema de suporte para o tratamento e prevenção de doenças das veias
WO2009106831A3 (en) Pharmaceutical composition comprising naltrexone
EA201290098A1 (ru) Способ получения полимерных композиций на основе проантоцианидина для фармацевтических форм
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2008022345A3 (en) Compositions and methods for inhibiting cytochrome p450
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2009108857A3 (en) Combination therapy for prostate cancer
CL2014003607A1 (es) Compuestos derivados de benzodioxol, inhibidores de la acetilcolinesterasa; metodo de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o el tratamiento de la enfermedad de alzheimer.
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
WO2009037705A3 (en) Esters of n-phenylanthranilic acid for use in the treatment of cancer and inflammation
EP2636677A4 (en) CDK-HEMMENDES PYRROLOPYRIMIDINONCARBOXAMID DERIVATIVE OR PHARMACEUTICAL ACCEPTABLE SALT AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEREOF FOR THE PREVENTION OR TREATMENT OF LIVER CELL CARCINOMA
GB201004761D0 (en) Method
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: RB PHARMACEUTICALS LIMITED (GB)

B25D Requested change of name of applicant approved

Owner name: INDIVIOR UK LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: INDIVIOR UK LIMITED (GB)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: INDIVIOR UK LIMITED (GB)

Free format text: FOI ANULADO O DESPACHO 25.7 DA RPI 2397 DE 13/12/2016 POR TER SIDO INDEVIDO.

B25D Requested change of name of applicant approved

Owner name: INDIVIOR UK LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]